Company
Sanofi
Sanofi has 83 drugs tracked on RxWires: 9 post-market, 10 approved, 21 in Phase 3, 26 in Phase 2, 5 in Phase 1/2, 11 in Phase 1.
- Ticker
- SNY
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Enoxaparin | Post-Market | Thromboembolism |
| Efanesoctocog alfa | Post-Market | Factor VIII Deficiency |
| Insulin Glulisine | Post-Market | Diabetes Mellitus |
| Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation | Post-Market | Influenza |
| live attenuated and inactivated influenza vaccines | Post-Market | Influenza |
| Insulin Glargine (HOE901) [Lantus] | Post-Market | Diabetes Mellitus, Type 2 |
| Dupilumab | Post-Market | Atopic Dermatitis |
| INSULIN GLARGINE | Post-Market | Diabetes Mellitus |
| Belumosudil | Post-Market | Chronic Graft Versus Host Disease |
| SLO-BID | Approved | |
| BRICANYL | Approved | |
| TOUJEO | Approved | |
| XYZAL ALLERGY 24HR | Approved | |
| GLYBURIDE (MICRONIZED) | Approved | |
| ZALTRAP | Approved | |
| DV | Approved | |
| NOVAFED | Approved | |
| LASIX | Approved | |
| PHISOHEX | Approved | |
| Sarilumab | Phase 3 | Rheumatoid Arthritis |
| Frexalimab | Phase 3 | Multiple Sclerosis |
| Dupilumab coformulated with berahyaluronidase alfa | Phase 3 | Dermatitis Atopic |
| rFVIIIFc | Phase 3 | Hemophilia A |
| Alirocumab | Phase 3 | Hypercholesterolemia |
| Measles, combinations with mumps and rubella, live attenuated | Phase 3 | Yellow Fever Immunization |
| Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH | Phase 3 | Influenza Immunization |
| rFIXFc | Phase 3 | Hemophilia B |
| SR34006 | Phase 3 | Pulmonary Embolism |
| AVE5530 | Phase 3 | Hypercholesterolemia |
| ciclesonide (XRP1526) | Phase 3 | Respiratory Tract Diseases |
| Satavaptan | Phase 3 | Ascites |
| Duvakitug | Phase 3 | Ulcerative Colitis |
| High-Dose Inactivated, Split-Virion Influenza Vaccine | Phase 3 | Orthomyxoviridae Infection |
| Generic = Plerixafor | Phase 3 | Lymphoma (Non-Hodgkin's Lymphoma) |
| AFLIBERCEPT AVE0005 | Phase 3 | Colorectal Cancer Metastatic |
| Lactic Acid | Phase 3 | Hygiene |
| alfuzosin (SL770499) | Phase 3 | Urinary Bladder Neurogenic |
| eplivanserin (SR46349) | Phase 3 | Sleep Initiation and Maintenance Disorders |
| rilzabrutinib | Phase 3 | Immune Thrombocytopenia |
| Venglustat | Phase 3 | Gaucher's Disease Type III |
| aminopterin | Phase 2 | Endometrial Cancer |
| Myozyme | Phase 2 | Pompe Disease Late-Onset |
| SAR443820 | Phase 2 | Amyotrophic Lateral Sclerosis |
| SAR445877 | Phase 2 | Gastric Cancer |
| Teplizumab | Phase 2 | Type 1 Diabetes Mellitus |
| SAR442970 | Phase 2 | Ulcerative Colitis |
| SAR448851 | Phase 2 | Dementia, Alzheimer's Type |
| SAR444656 (KT-474) | Phase 2 | Atopic Dermatitis |
| brivekimig | Phase 2 | Crohn's Disease |
| Lunsekimig | Phase 2 | Chronic Rhinosinusitis With Nasal Polyps |
| Thymoglobulin | Phase 2 | Non-Hodgkin's Lymphoma |
| Fabrazyme (agalsidase beta) | Phase 2 | Fabry Disease |
| Isatuximab | Phase 2 | Multiple Myeloma |
| G-CSF Plus Plerixafor | Phase 2 | Multiple Myeloma |
| Cabazitaxel | Phase 2 | Metastatic Castration Resistant Prostate Cancer |
| Insulin glargine /lixisenatide Fixed Ratio Combination | Phase 2 | Type 2 Diabetes Mellitus |
| FOLFOX 4 | Phase 2 | Esophageal Neoplasms |
| Docetaxel | Phase 2 | Stomach Neoplasms |
| Taxotere | Phase 2 | Prostate Cancer |
| Dupilumab SAR231893/REGN668 | Phase 2 | Asthma |
| Non pegylated liposomal doxorubicin and docetaxel | Phase 2 | Breast Cancer |
| aflibercept | Phase 2 | Mucinous Adenocarcinoma of the Colon |
| SAR445419 | Phase 2 | Allogenic Stem Cell Transplantation |
| Capecitabine | Phase 2 | Colorectal Cancer Metastatic |
| Itepekimab SAR440340 | Phase 2 | Chronic Obstructive Pulmonary Disease |
| ZD6474 (vandetanib) | Phase 2 | Thyroid Cancer |
| Oxaliplatin | Phase 1/2 | Richter's Transformation |
| ATN-103 10 mg q4wks | Phase 1/2 | Rheumatoid Arthritis |
| SAR402663 | Phase 1/2 | Neovascular Age-related Macular Degeneration |
| Vociprotafib | Phase 1/2 | Metastatic Neoplasm |
| Clofarabine | Phase 1/2 | Acute Lymphoblastic Leukemia |
| SAR408701 | Phase 1 | Neoplasm Malignant |
| Chlamydia mRNA Vaccine | Phase 1 | Chlamydia Trachomatis Immunization |
| alirocumab SAR236553 (REGN727) | Phase 1 | Hypercholesterolemia |
| DNL747 | Phase 1 | Amyotrophic Lateral Sclerosis |
| Tusamitamab ravtansine | Phase 1 | Neoplasm |
| Bortezomib | Phase 1 | Non Small Cell Lung Cancer |
| SAR443216 IV | Phase 1 | Neoplasm Malignant |
| ALN-AT3SC | Phase 1 | Hemophilia A |
| SAR245408 (XL147) | Phase 1 | Solid Tumors |
| SAR442257 | Phase 1 | Neoplasm Malignant |
| Ombrabulin (AVE8062) | Phase 1 | Advanced Solid Tumors |
| AZD6244 | Not Applicable | Thyroid Cancer |
Latest
- Rilzabrutinib moved to Phase 3
- Belumosudil moved to Post-Market
- Frexalimab moved to Phase 3
- Label updated: LEVOCETIRIZINE DIHYDROCHLORIDE
- Label updated: INSULIN GLARGINE
Follow Sanofi on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.